Olanzapine plus modafinil

PreclinicalSmall molecule

NNeuropsychiatric Research Institute, Fargo, North Dakota

Olanzapine plus modafinil is one of 3 small molecule programs targeting Weight Gain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight GainCompleted

Weight GainPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Weight Gain

#DrugCompanyPhaseTrials

Niacor

AbbVie

Phase 1

—2

Qsymia 7.5 Miligrams

UUniversity of Minnesota

Phase 3

1 3

Olanzapine plus modafinil

NNeuropsychiatric Research Institute, Fargo, North Dakota

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Weight Gain1 trial

Effects of Modafinil on Olanzapine Weight Gain

Completed·NNeuropsychiatric Research Institute, Fargo, North Dakota·N/A·NCT00636896·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Olanzapine plus modafinil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Olanzapine plus modafinil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Olanzapine plus modafinil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neuropsychiatric Research Institute, Fargo, North Dakota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNeuropsychiatric Research Institute, Fargo, North Dakota

Olanzapine plus modafinil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Weight Gain1 trial

References

Drug Info

Quick Facts

Related News